NASDAQ:VRPX Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 05/27/2026 12:42 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Virpax Pharmaceuticals Stock (NASDAQ:VRPX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Virpax Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.00▼$0.48Volume151 shsAverage Volume1,084 shsMarket Capitalization$124.20P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) is a clinical-stage specialty pharmaceutical company dedicated to the research, development and manufacturing of vaccines and injectable therapeutics. Headquartered in Fort Lauderdale, Florida, the company leverages proprietary formulation and drug‐delivery platforms to enhance the stability, bioavailability and tolerability of its product candidates. Virpax’s integrated model spans early-stage discovery through cGMP manufacturing, enabling seamless progression from laboratory proof‐of‐concept to large-scale production. Virpax’s pipeline encompasses a range of vaccine candidates targeting diseases such as rabies, herpes zoster and other infectious threats. Its proprietary adjuvant systems and lipid-based delivery technologies are designed to optimize immune responses while minimizing reactogenicity. In addition to vaccines, the company develops specialty injectable formulations for small molecules and biologics, addressing challenges related to solubility, absorption and patient compliance. Virpax advances its programs through collaborations with academic institutions, government agencies and contract development organizations, reinforcing its focus on both endemic and emerging health risks. Since its founding, Virpax has invested in scalable U.S. manufacturing capabilities that adhere to current Good Manufacturing Practices. The company’s strategic emphasis on vaccine innovation and formulation expertise positions it to serve domestic and selected international markets. As Virpax progresses its pipeline through preclinical and clinical milestones, its leadership continues to pursue partnerships and licensing opportunities to accelerate the development and commercialization of its vaccine and injectable portfolios.AI Generated. May Contain Errors. Read More Receive VRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRPX Stock News HeadlinesVirpax Pharmaceuticals stock plummets on Nasdaq delisting newsApril 3, 2025 | investing.comVirpax Pharmaceuticals Inc trading halted, news pendingMarch 21, 2025 | markets.businessinsider.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.May 28 at 1:00 AM | Porter & Company (Ad)Virpax reports positive results in Probudur dog studyMarch 20, 2025 | investing.comVirpax receives positive Probudur results for dose range studyMarch 20, 2025 | markets.businessinsider.comVirpax Pharmaceuticals announces 1-for-25 reverse stock splitMarch 20, 2025 | markets.businessinsider.comVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDMarch 18, 2025 | finance.yahoo.comVirpax Pharmaceuticals files to sell common stock and warrants, no amount givenMarch 18, 2025 | markets.businessinsider.comSee More Headlines VRPX Stock Analysis - Frequently Asked Questions How have VRPX shares performed this year? Virpax Pharmaceuticals' stock was trading at $0.0111 at the beginning of 2026. Since then, VRPX shares have decreased by 99.1% and is now trading at $0.0001. When did Virpax Pharmaceuticals' stock split? Shares of Virpax Pharmaceuticals reverse split on Friday, March 1st 2024.The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virpax Pharmaceuticals IPO? Virpax Pharmaceuticals (VRPX) raised $20 million in an initial public offering (IPO) on Wednesday, February 17th 2021. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of Virpax Pharmaceuticals? Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virpax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virpax Pharmaceuticals investors own include AMC Entertainment (AMC), Dare Bioscience (DARE), Rallybio (RLYB), Plug Power (PLUG), SNDL (SNDL) and SOS (SOS). Company Calendar Today5/28/2026Next Earnings (Estimated)5/28/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRPX CIK1708331 Webwww.virpaxpharma.com Phone610-727-4597FaxN/AEmployees7Year Founded2017Profitability EPS (Trailing Twelve Months)($123.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.19 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,554.34% Return on Assets-338.29% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / Book0.00Miscellaneous Outstanding Shares1,242,000Free Float4,707,000Market Cap$124.20 OptionableNot Optionable Beta2.56 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:VRPX) was last updated on 5/28/2026 by MarketBeat.com Staff. From Our PartnersThe math on the SpaceX IPO is brokenSpaceX is expected to go public at a $1.75 trillion valuation. For investors to see a 10x return, the company ...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredHow daily 'stock bets' hit 87% of the timeA daily trading system claims an 87% win rate on short-term stock plays - and it runs just one hour a day, fro...Trade To Close | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman, and Nvidia CEO Jensen Huang may hold the answer to ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
